207 Porter St,

Boston,

MA,

US,

ZIP: 02128

Phone: (+1) 6174554188

The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate, measure and predict the immune response to your gene therapy candidate.

In the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays.

Incorporating insights from leading immunological, bioanalytical, and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity.

With 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies.

Tickets    https://go.evvnt.com/1204401-2?pid=1052
Brochure https://go.evvnt.com/1204401-3?pid=1052

Prices:
Drug Developer Pricing (Conference + Workshop Day) USD 3896.00
Drug Developer Pricing (Conference Only) USD 2999.00
Academic Pricing (Conference + Workshop Day) USD 3196.00
Academic Pricing (Conference Only) USD 2599.00
Vendor Pricing (Conference + Workshop Day) USD 4896.00
Vendor Pricing (Conference Only) USD 3999.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Anna Majowicz, Preclinical Immunology Lead, Spark Therapeutics, Allison Keeler-Klunk, Assistant Professor, University of Massachusetts Medical School, William Lagor, Associate Professor - Molecular & Cellular Biology, Baylor College of Medicine, Roland Herzog, Director - Gene, Cell Therapy Program, Indiana University School of Medicine, Rebecca Xicluna, Post Doctoral Fellow, Roche, Boris Gorovits, Vice President, Sana Biotechnology, Olga Uspenskaya, VP clinical development, Prevail Therapeutics, Jonathan Schwartz, Chief Medical Officer, Rocket Pharmaceuticals, Joshua Friedman, Head Translational Science, Spark Therapeutics, Rajakumar Mandraju, Principal Scientist, Modalis Therapeutics, Dongsheng Duan, Professor, University of Missouri School of Medicine, Kei Kishimoto, CSO, Selecta Biosciences Inc., Steen Klysner, Chief Executive Officer, Amarna Therapeutics, Hildegund Ertl, Professor - Vaccine & Immunotherapy Center, The Wistar Institute, Josh Holter, Scientist, Sangamo Therapeutics, Laura Salazar-Fontana, Independent Consultant, Lillian Falese, Associate Director - Bioanalytical Development, Spirovant Sciences, Priya Chockalingam, Vice President & Head of Clinical Bioanalytics & Translational Sciences, Beam Therapeutics, William Quinn, Director Immunology, Kriya Therapeutics, Jean-Philippe Combal, Co-Founder & Chief Executive Officer, Vivet Therapeutics, Hélène Haegel, Principal Scientist, ImmunologyRoche, Katherine Block Director - Biomarker Sciences, Sangamo Therapeutics, Liching cao, Director - Bioanalytical Operations, Sangamo Therapeutics, Shari Gordon, Senior Director - Immunology, AskBio, Jatin Narula, Principal Scientist Biomedicine Design, Pfizer, Moanaro Biswas, Assistant Professor - Research, Indiana University, Roberto Calcedo, Vice President - Preclinical & Immunology, Affinia Therapeutics, Ashlyn Bassiri, Vice President - Immunology, Kriya Therapeutics, Inderpal Singh, Immunogenicity Prediction Lead, Spark Therapeutics